Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223

Abstract

Background Until recently, few molecular aberrations were recognized in acute lymphoblastic leukemia of T-cell origin; novel lesions have recently been identified and a certain degree of overlap between acute myeloid leukemia and T-cell acute lymphoblastic leukemia has been suggested. To identify novel T-cell acute lymphoblastic leukemia entities, gene expression profiling was performed and clinico-biological features were studied. Design and Methods Sixty-nine untreated adults with T-cell acute lymphoblastic leukemia were evaluated by oligonucleotide arrays: unsupervised and supervised analyses were performed. The up-regulation of myeloid genes and miR-223 expression were validated by quantitative polymerase chain reaction analysis. Results Using unsupervised clustering, we identified five subgroups. Of these, one branch included seven patients whose gene expression profile resembled that of acute myeloid leukemia. These cases were characterized by over-expression of a large set of myeloid-related genes for surface antigens, transcription factors and granule proteins. Real-time quantitative polymerase chain reaction analysis confirmed over-expression of MPO, CEBPA, CEBPB, GRN and IL8. We, therefore, evaluated the expression levels of miR-223, involved in myeloid differentiation: these cases had significantly higher levels of miR-223 than had the other cases of T-cell acute lymphoblastic leukemia, with values comparable to those observed in acute myeloid leukemia. Finally, these patients appear to have an unfavorable clinical course. Conclusions Using gene profiling we identified a subset of adult T-cell acute lymphoblastic leukemia, accounting for 10% of the cases analyzed, which displays myeloid features. These cases were not recognized by standard approaches, underlining the importance of gene profiling in identifying novel acute leukemia subsets. The recognition of this subgroup may have clinical, prognostic and therapeutic implications

MicroRNA-223 Regulates Cyclin E Activity by Modulating Expression of F-box and WD-40 Domain Protein 7

“…Although FBXW7 is one of several identified targets of this microRNA (51,55,56), the potency of Fbw7 as a tumor suppressor and the frequency at which it is mutated in human cancers suggests that its down-regulation through miR-223 overexpression could be an important event in the development of some cancers. For example, a recent report has described increased expression of miR-223 in some T-cell acute lymphoblastic leukemia cases, a leukemia subtype in which FBXW7 loss-of-function mutations are frequently found (14,57). Possibly, miR-223 dysregulation could provide a means for impairing the tumor suppressor activities of Fbw7 in cell transformation without direct mutation of FBXW7.…”

Abnormal MicroRNA Expression in Ts65Dn Hippocampus and Whole Blood: Contributions to Down Syndrome Phenotypes

“…In addition to its role in the hippocampus, miR-223, which we found upregulated in Ts65Dn blood, has been implicated in myeloid differentiation and its overexpression has been associated with a subset of adult T cell acute lymphoblastic leukemia [126], a highly prevalent trait in DS subjects [125]. miR-223 is also the highest expressed megakaryocytic miRNA in primary myelofibrosis and essential thrombocythemia [127].…”

SQSTM1-NUP214: a new gene fusion in adult T-cell acute lymphoblastic leukemia

“…The prevalence at present is one in a total of 136 cases; 69 in the GEP series 4 and 67 screened in the present report by RT-PCR.…”

“…Twenty-eight mutation-negative EU study IC (historically diagnosed with type 1 VWD 2 ) were investigated, ten demonstrating complete co-segregation of disease phenotype with VWF, 4 the remainder from small families of 3 or less individuals (non-informative for linkage). Genomic DNA was available for IC, their affected (AFM) and unaffected (UFM) family members, and from healthy controls (HC).…”